Shenzhen Institute for Innovation and Translational Medicine Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2015
NCT02456350
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Shenzhen Institute for Innovation and Translational Medicine

Active Ingredients

Drugs in Phase 2 Trials (3)

cd19 car-t cells (3 trials)

cyclophosphamide (cytoxan) (2 trials)

fludarabine (fludara) (2 trials)

Drugs in Phase 1 Trials (1)

anti-ny eso-1 tcr-transduced t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Multiple Myeloma (Phase 1)

Neuroblastoma (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Sarcoma, Synovial (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4